Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

Table S1 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases

<p>Supplementary Table S1</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Noor Jailkhani (16015810) (author)
Diğer Yazarlar:	Karl R. Clauser (16015813) (author), Howard H. Mak (14958336) (author), Steffen Rickelt (14942629) (author), Chenxi Tian (16015816) (author), Charles A. Whittaker (15038249) (author), Kenneth K. Tanabe (16015819) (author), Stephen R. Purdy (16015822) (author), Steven A. Carr (14942649) (author), Richard O. Hynes (14942641) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Tumor Biology Molecular and Cellular Biology Immuno-oncology Methods and Technology Breast Cancer Imaging Positron emission tomography (PET) Small animal imaging Immunology Antibodies/immunoconjugates Proteomics Tumor Microenvironment
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Table S2 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Yazar:: Noor Jailkhani (16015810)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Yazar:: Noor Jailkhani (16015810)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Yazar:: Xiaojiang Duan (15439264)
Baskı/Yayın Bilgisi: (2025)

FigureS1 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS10 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS2 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS3 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS4 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS5 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS6 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS7 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS8 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

FigureS9 from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS 1a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS1b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS1c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS1d from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS2a from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS2b from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary MovieS2c from Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer
Yazar:: Jonathan Chou (14957015)
Baskı/Yayın Bilgisi: (2025)

Supplementary Data S1 from Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer
Yazar:: Steven B. Maron (15044607)
Baskı/Yayın Bilgisi: (2025)

Alternative Ion-Pairing Modifiers Should Be Investigated in Low-Input and Single-Cell Proteomics
Yazar:: Colten D. Eberhard (17729446)
Baskı/Yayın Bilgisi: (2025)

Quantitative Proteomics Links Mitochondrial Dysfunction to Metabolic Changes and Epithelial Differentiation Defects in Hyperoxia-Exposed Neonatal Airway Cells
Yazar:: Abhrajit Ganguly (21540245)
Baskı/Yayın Bilgisi: (2025)

Table 1_Cerebrospinal fluid proteomic profiling reveals potential biomarkers and altered pathways in myotonic dystrophy type 1.docx
Yazar:: Marwa Zafarullah (12527002)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Figure 6 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Figure 7 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Imaging Glioblastoma Response to Radiotherapy Using <sup>2</sup>H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Yazar:: Friederike Hesse (14958870)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Yazar:: Vinton W.T. Cheng (15020397)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Yazar:: Vinton W.T. Cheng (15020397)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Yazar:: Vinton W.T. Cheng (15020397)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Yazar:: Vinton W.T. Cheng (15020397)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
Yazar:: Vinton W.T. Cheng (15020397)
Baskı/Yayın Bilgisi: (2025)

Cannot write session to /tmp/vufind_sessions/sess_bijtavmlpfab1vnpsm2skei0v7